EUVIMEDEUVIMED entdecken
VergleichsstudieKlinische Studie

CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [18F]FDG PET/CT

Wei Guo, Liang Cheng, Xinglu Zhou, Yue Zhao, Hui Chen, Yubai Zhang, Yudie Qin, Wei Liu, Geng Hu, Xinyue Yang, Huihui You, Wenyi Wei und 3 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-025-07748-4 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Wei Guo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of PET/CT-MR, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Carcinoma, Renal Cell, Fluorodeoxyglucose F18, Kidney Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Heilongjiang Provincial Natural Science Foundation of China, Postgraduate Research & Practice Innovation Program of Harbin Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the diagnostic performance and staging of the novel CAIX-targeted tracer [18F]AlF-NYM005 in clear cell renal cell carcinoma (ccRCC), and directly compare it with that of [18F]FDG PET/CT. METHODS: This prospective single-center trial enrolled 61 patients (41 male, 20 female; median age, 62.0 years). Participants underwent [18F]AlF-NYM005 and [18F]FDG PET/CT within one week. A composite reference standard including histopathology, follow-up, or multimodal imaging was used to define 331 lesions (35 renal, 296 metastatic). Diagnostic performance, standardized uptake value (SUV) and tumour-node-metastasis (TNM) classifications were evaluated and compared between the two tracers. RESULTS: For renal tumours, [18F]AlF-NYM005 PET/CT demonstrated significantly superior diagnostic performance to [18F]FDG (P < 0.001), with higher sensitivity (82.1% vs. 42.9%), specificity (85.7% vs. 42.9%), positive predictive value (95.8% vs. 75.0%), negative predictive value (54.5% vs. 15.8%), and accuracy (82.9% vs. 42.9%). In metastatic lesions, [18F]AlF-NYM005 detected significantly more lesions (248 vs. 156, P < 0.001), particularly in lymph nodes, pleura/peritoneum, and lung. Compared with [18F]FDG, [18F]AlF-NYM005 PET/CT consequently altered the staging/restaging of approximately one-third of patients. Quantitative analysis demonstrated higher tumour uptake (SUVmax) with [18F]AlF-NYM005 in renal tumours (11.8 vs. 3.5) and metastatic lesions (5.0 vs. 3.2), along with a higher tumour-to-liver ratio (3.9 vs. 1.6). Immunohistochemistry showed that 66.7% of samples had intermediate/strong CAIX expression, which was positively correlated with [18F]AlF-NYM005 uptake, pT stage, and WHO/ISUP grade. CONCLUSION: [18F]AlF-NYM005 PET/CT was superior to [18F]FDG in the detection of renal tumours and metastatic lesions, demonstrating higher radiotracer uptake and more accurate staging. TRIAL REGISTRATION: Chinese Clinical Trial Registry. ChiCTR2400085765, Registered 18 June 2024, retrospectively registered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyCarcinoma, Renal CellFluorodeoxyglucose F18Kidney NeoplasmsCarbonic Anhydrase IXHumansFemaleMiddle AgedMaleAgedRadiopharmaceuticalsAdultProspective StudiesAged, 80 and over

Stichwörter der Autor:innen

Carbonic anhydrase IXClear cell renal cell carcinomaPET/CT[18F]AlF-NYM005[18F]FDG

Substanzen

Fluorodeoxyglucose F18Carbonic Anhydrase IXRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of PET/CT-MR, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
  • Department of Urology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
  • Department of Radiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150000, China.
  • Department of PET/CT-MR, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China. wangkezheng9954001@163.com.

ORCID-Profile: Dayong Hou, Hao Jiang, Kezheng Wang

Förderung

  • National Natural Science Foundation of China
  • Heilongjiang Provincial Natural Science Foundation of China
  • Postgraduate Research & Practice Innovation Program of Harbin Medical University
  • Key Project of Harbin Medical University Cancer Hospital Climbing Funding
  • Key Innovation Technology Project Harbin Medical University Cancer Hospital Innovation Technology Funding

Zitieren

APA

Guo, W., Cheng, L., Zhou, X., Zhao, Y., Chen, H., Zhang, Y., Qin, Y., Liu, W., Hu, G., Yang, X., You, H., Wei, W., Hou, D., Jiang, H., & Wang, K. (2026). CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07748-4

Vancouver

Guo W, Cheng L, Zhou X, Zhao Y, Chen H, Zhang Y, et al. CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07748-4

BibTeX
@article{Guo2026,
  author = {Guo, Wei and Cheng, Liang and Zhou, Xinglu and Zhao, Yue and Chen, Hui and Zhang, Yubai and Qin, Yudie and Liu, Wei and Hu, Geng and Yang, Xinyue and You, Huihui and Wei, Wenyi and Hou, Dayong and Jiang, Hao and Wang, Kezheng},
  title = {CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [18F]FDG PET/CT},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-025-07748-4}
}
Kostenlos starten →